When should caution be exercised when using PTH receptor agonists?

The correct response highlights the importance of monitoring patients for hypercalcemia when using parathyroid hormone (PTH) receptor agonists. These medications can increase calcium levels because they stimulate bone resorption as well as formation, which may lead to elevated serum calcium levels. In patients already predisposed to hypercalcemia, the use of PTH receptor agonists can exacerbate this condition, leading to potential complications such as kidney stones, cardiovascular issues, or neurological symptoms.

It is vital to have this caution in mind to ensure patient safety and to monitor calcium levels diligently during treatment. While there may be considerations with kidney disease, a history of fractures, or osteoporosis, these factors are typically managed through appropriate treatment plans that do not necessarily contraindicate the use of PTH receptor agonists. Body calcium levels, however, demand a particularly vigilant approach to avoid the risks associated with hypercalcemia.